Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Bank of Russia registered Novabev Group's additional share issue

8/5/24 BELU

Rossetti North Caucasus reported for 6 months of 2024 by RAS

8/5/24 MRKK

Ozon reported for 6 months of 2024

8/5/24 OZON

Ozon's turnover grew by 78%

8/5/24 OZON

KGC reported for 6 months of 2024 by RAS

8/5/24 KGKC

Rusagro reported for 6 months of 2024 by IFRS

8/5/24 AGRO

Levenguc reported for 6 months of 2024 by RAS

8/5/24 LVHK

Nauka reported for 6 months of 2024 by RAS

8/5/24 NAUK

TNS Energo Nizhny Novgorod reported for 6 months of 2024 by RAS

8/5/24 NNSB

Board of Directors of Territorial Generating Company № 14 recommended dividends

8/5/24 TGKN